NEUROCRINE BIOSCIENCES INC (NBIX)
Biological Products, (No Diagnostic Substances)
Latest Price
$185.50
TTM P/E
28.54
Normalized P/E
62.67
Div Yield
--
Book Value
33.90
P/B Ratio
5.47
Valuation metrics
adjust assumptions →EPS: $4.67
Book value / share: $32.50
Formula: √(22.5 × EPS × BVPS)
Graham Number
$58.44
65% downside
Norm. op. income: $249M (median of 7yr)
Tax rate: 26%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$29.16
83% downside
Base FCF: $362M (median of recent 5yr)
Growth: 25%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$279.67
+68% upside
EPS: $4.67
Target P/E: 56×
Formula: EPS × P/E
P/E Fair Value
$261.52
+57% upside
Institutional Ownership
88.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13.39M | $1.76B | 13.31% | +555.0K | 2026-03-31 |
| Dodge & Cox | 5.46M | $719.0M | 5.43% | -47.0K | 2026-03-31 |
| AQR CAPITAL MANAGEMENT LLC | 4.94M | $650.0M | 4.91% | +1.67M | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.73M | $622.0M | 4.70% | -- | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.51M | $594.0M | 4.48% | -- | 2026-03-31 |
| STATE STREET CORP | 4.35M | $573.0M | 4.33% | +111.8K | 2026-03-31 |
| RENAISSANCE TECHNOLOGIES LLC | 2.42M | $318.0M | 2.40% | +180.1K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.14M | $280.0M | 2.12% | +77.4K | 2026-03-31 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.49M | $196.0M | 1.48% | +97.9K | 2026-03-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.39M | $183.0M | 1.38% | -355.0K | 2026-03-31 |